Literature DB >> 11967553

Listening to silence and understanding nonsense: exonic mutations that affect splicing.

Luca Cartegni1, Shern L Chew, Adrian R Krainer.   

Abstract

Point mutations in the coding regions of genes are commonly assumed to exert their effects by altering single amino acids in the encoded proteins. However, there is increasing evidence that many human disease genes harbour exonic mutations that affect pre-mRNA splicing. Nonsense, missense and even translationally silent mutations can inactivate genes by inducing the splicing machinery to skip the mutant exons. Similarly, coding-region single-nucleotide polymorphisms might cause phenotypic variability by influencing splicing accuracy or efficiency. As the splicing mechanisms that depend on exonic signals are elucidated, new therapeutic approaches to treating certain genetic diseases can begin to be explored.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11967553     DOI: 10.1038/nrg775

Source DB:  PubMed          Journal:  Nat Rev Genet        ISSN: 1471-0056            Impact factor:   53.242


  790 in total

1.  Distribution and characterization of regulatory elements in the human genome.

Authors:  Jacek Majewski; Jurg Ott
Journal:  Genome Res       Date:  2002-12       Impact factor: 9.043

2.  Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment.

Authors:  Jagjeet K Kang; Alberto Malerba; Linda Popplewell; Keith Foster; George Dickson
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

3.  Missense mutations in hMLH1 and hMSH2 are associated with exonic splicing enhancers.

Authors:  Ivan P Gorlov; Olga Y Gorlova; Marsha L Frazier; Christopher I Amos
Journal:  Am J Hum Genet       Date:  2003-10-01       Impact factor: 11.025

4.  Conserved sequence elements associated with exon skipping.

Authors:  Elana Miriami; Hanah Margalit; Ruth Sperling
Journal:  Nucleic Acids Res       Date:  2003-04-01       Impact factor: 16.971

Review 5.  Nuclear translation: what is the evidence?

Authors:  James E Dahlberg; Elsebet Lund; Elizabeth B Goodwin
Journal:  RNA       Date:  2003-01       Impact factor: 4.942

6.  Intronic sequences flanking alternatively spliced exons are conserved between human and mouse.

Authors:  Rotem Sorek; Gil Ast
Journal:  Genome Res       Date:  2003-07       Impact factor: 9.043

7.  A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.

Authors:  Sophia Adamia; Benjamin Haibe-Kains; Patrick M Pilarski; Michal Bar-Natan; Samuel Pevzner; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; John Burke; Ilene Galinsky; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Richard Stone; James D Griffin
Journal:  Clin Cancer Res       Date:  2013-11-27       Impact factor: 12.531

8.  Antagonistic regulation of alpha-actinin alternative splicing by CELF proteins and polypyrimidine tract binding protein.

Authors:  Natalia Gromak; Arianne J Matlin; Thomas A Cooper; Christopher W J Smith
Journal:  RNA       Date:  2003-04       Impact factor: 4.942

9.  Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts.

Authors:  Leigh A Skordis; Matthew G Dunckley; Baigong Yue; Ian C Eperon; Francesco Muntoni
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

10.  Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense.

Authors:  Annemieke Aartsma-Rus; Anneke A M Janson; Wendy E Kaman; Mattie Bremmer-Bout; Gert-Jan B van Ommen; Johan T den Dunnen; Judith C T van Deutekom
Journal:  Am J Hum Genet       Date:  2003-12-16       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.